MR has become a reliable and noninvasive method of hepatic iron quantification. Currently, most of the hepatic iron quantification is performed on 1.5？T MR, and the biopsy measurements have been paired with and values for 1.5？T MR. As the use of 3？T MR scanners is steadily increasing in clinical practice, it has become important to evaluate the practicality of calculating iron burden at 3？T MR. Hepatic iron quantification on 3？T MR requires a better understanding of the process and more stringent technical considerations. The purpose of this work is to focus on the technical challenges in establishing a relationship between values at 1.5？T MR and 3？T MR for hepatic iron concentration (HIC) and to develop an appropriately optimized MR protocol for the evaluation of values in the liver at 3？T magnetic field strength. We studied 22 sickle cell patients using multiecho fast gradient-echo sequence (MFGRE) 3？T MR and compared the results with serum ferritin and liver biopsy results. Our study showed that the quantification of hepatic iron on 3？T MRI in sickle cell disease patients correlates well with clinical blood test results and biopsy results. 3？T MR liver iron quantification based on MFGRE can be used for hepatic iron quantification in transfused patients. 1. Introduction Presence of iron in the body is essential as it forms an important component of metabolic and biological processes. On the contrary, its excess can be a serious health risk for chronically transfused patients, for example, thalassemia and sickle cell disease patients [1, 2]. End organ damage can result from deposition of excessive iron in organs such as hepatic parenchyma, endocrine organs, and cardiac cells [3–5]. Total body iron load is the major determining factor of clinical outcome in all forms of systemic iron overload. Accurate assessment of total body iron load is crucial for managing iron chelation therapy to avoid iron toxicity while preventing the toxicity of excess chelator administration. Serum ferritin concentration, transferrin saturation, and serum iron concentration are serum makers for biochemical measurement of total body iron load. In most cases, these correlate well with the total iron burden; however, certain factors like infection, inflammation, and malignancy could modify these, and therefore these may not always correctly reflect tissue iron levels [6, 7]. Hepatic iron concentration has been shown to be a reliable pointer of total body iron stores in patients with transfusion-related iron overload. Repeated assessments of the hepatic iron concentration can
References
[1]
E. B. Fung, P. Harmatz, M. Milet et al., “Morbidity and mortality in chronically transfused subjects with Thalassemia and Sickle Cell Disease: a report from the multi-center study of iron overload,” The American Journal of Hematology, vol. 82, no. 4, pp. 255–265, 2007.
[2]
S. K. Ballas, “Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease,” Seminars in Hematology, vol. 38, supplement 1, no. 1, pp. 30–36, 2001.
[3]
C. Hershko, G. Graham, G. W. Bates, and E. A. Rachmilewitz, “Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity,” British Journal of Haematology, vol. 40, no. 2, pp. 255–263, 1978.
[4]
J. G. Goddard and G. D. Sweeney, “Ferric nitrilotriacetate: a potent stimulant of in vivo lipid peroxidation in mice,” Biochemical Pharmacology, vol. 32, no. 24, pp. 3879–3882, 1983.
[5]
C. Hershko, G. Link, A. M. Konijn, and Z. I. Cabantchik, “Objectives and mechanism of iron chelation therapy,” Annals of the New York Academy of Sciences, vol. 1054, pp. 124–135, 2005.
[6]
E. Angelucci, G. M. Brittenham, C. E. McLaren et al., “Hepatic iron concentration and total body iron stores in thalassemia major,” The New England Journal of Medicine, vol. 343, no. 5, pp. 327–331, 2000.
[7]
E. Voskaridou, M. Douskou, E. Terpos et al., “Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease,” British Journal of Haematology, vol. 126, no. 5, pp. 736–742, 2004.
[8]
E. Voskaridou, M. Douskou, E. Terpos et al., “Deferiprone as an oral iron chelator in sickle cell disease,” Annals of Hematology, vol. 84, no. 7, pp. 434–440, 2005.
[9]
L. J. Anderson, S. Holden, B. Davis et al., “Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload,” European Heart Journal, vol. 22, no. 23, pp. 2171–2179, 2001.
[10]
J. C. Wood, C. Enriquez, N. Ghugre et al., “MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients,” Blood, vol. 106, no. 4, pp. 1460–1465, 2005.
[11]
E. Angelucci, D. Baronciani, G. Lucarelli et al., “Needle liver biopsy in thalassaemia: analyses of diagnostic accuracy and safety in 1184 consecutive biopsies,” British Journal of Haematology, vol. 89, no. 4, pp. 757–761, 1995.
[12]
D. D. Stark, N. M. Bass, and A. A. Moss, “Nuclear magnetic resonance imaging of experimentally induced liver disease,” Radiology, vol. 148, no. 3, pp. 743–751, 1983.
[13]
H. G. Klein, D. R. Spahn, and J. L. Carson, “Red blood cell transfusion in clinical practice,” The Lancet, vol. 370, no. 9585, pp. 415–426, 2007.
[14]
R. Raghupathy, D. Manwani, and J. A. Little, “Iron overload in sickle cell disease,” Advances in Hematology, vol. 2010, Article ID 272940, 9 pages, 2010.
[15]
T. V. Adamkiewicz, M. R. Abboud, C. Paley et al., “Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury,” Blood, vol. 114, no. 21, pp. 4632–4638, 2009.
[16]
V. J. Bush, T. P. Moyer, K. P. Batts, and J. E. Parisi, “Essential and toxic element concentrations in fresh and formalin-fixed human autopsy tissues,” Clinical Chemistry, vol. 41, no. 2, pp. 284–294, 1995.
[17]
N. D. Chasteen and P. M. Harrison, “Mineralization in ferritin: an efficient means of iron storage,” Journal of Structural Biology, vol. 126, no. 3, pp. 182–194, 1999.
[18]
P. D. Jensen, F. T. Jensen, T. Christensen, J. L. Nielsen, and J. Ellegaard, “Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias,” Blood, vol. 101, no. 1, pp. 91–96, 2003.
[19]
P. Storey, A. A. Thompson, C. L. Carqueville, J. C. Wood, R. A. de Freitas, and C. K. Rigsby, “R2* imaging of transfusional iron burden at 3T and comparison with 1.5T,” Journal of Magnetic Resonance Imaging, vol. 25, no. 3, pp. 540–547, 2007.
[20]
L. J. Noetzli, S. M. Carson, A. S. Nord, T. D. Coates, and J. C. Wood, “Longitudinal analysis of heart and liver iron in thalassemia major,” Blood, vol. 112, no. 7, pp. 2973–2978, 2008.
[21]
J. C. Wood, J. M. Tyszka, S. Carson, M. D. Nelson, and T. D. Coates, “Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease,” Blood, vol. 103, no. 5, pp. 1934–1936, 2004.
[22]
G. M. Brittenham, D. E. Farrell, and J. W. Harris, “Magnetic-susceptibility measurement of human iron stores,” The New England Journal of Medicine, vol. 307, no. 27, pp. 1671–1675, 1982.
[23]
E. Voskaridou, M. Douskou, E. Terpos et al., “Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease,” British Journal of Haematology, vol. 126, no. 5, pp. 736–742, 2004.
